A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Study Identifier
PCYC-1117-CA
CT.gov Identifier
NCT01744691
EudraCT Identifier
2012-004476-19
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
  • Blood Cancer - Small Lymphocytic Lymphoma (SLL)
    • Study Drug
  • Ibrutinib
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Documentation of del (17p13.1) * Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of systemic therapy. * Measurable nodal disease by computed tomography (CT)
    Exclusion Criteria:
    * History or current evidence of Richter's transformation or prolymphocytic leukemia * Prior hematologic stem cell transplantation \<6 months from study enrollment or any ongoing GVHD * Prior exposure to ibrutinib

    Protocol Summary

    An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

    Study Locations

    Location
    Status
    Location
    Phoenix, Arizona, United States
    Status
    Not applicable
    Location
    Duarte, California, United States
    Status
    Not applicable
    Location
    Greenbrae, California, United States
    Status
    Not applicable
    Location
    La Jolla, California, United States
    Status
    Not applicable
    Location
    Stanford, California, United States
    Status
    Not applicable
    Location
    Tampa, Florida, United States
    Status
    Not applicable
    Showing {first} - {last} of {total} Results